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INTRODUCTION
Graft-versus-leukemia (GVL) effects are antitumor
responses exerted by donor lymphocytes after hematopoietic
stem cell (HSC) transplantation. GVL activity occurs in
patients with myeloid [1] and lymphoid [2] leukemias, and
analogous antitumor responses have been identified in
patients with other malignancies, such as multiple myeloma
[3] and breast cancer [4]. Intere s t i n g l y, myeloid leukemias
seem especially sensitive to GVL activity. T cells are major
mediators of GVL responses, based on re p o rts that (1) T-cell
depletion of HSC grafts correlates with higher rates of
leukemic relapse [5-7], (2) the delayed infusion of T cells
can reverse relapse [8], and (3) human T-cell clones can tar-
get leukemic cells in vitro [9-11].
The epitopes recognized in the course of a GVL
response are still points of contention and may likely
involve both shared host alloantigens, which can also
induce graft-versus-host disease (GVHD), and unique tis-
sue- or tumor-specific antigens. Support for the existence
of alloreactive responses comes from the overall clinical
c o rrelation of decreased leukemic relapse rates for patients
with acute or chronic GVHD [12,13]. Some human minor
histocompatibility antigens, such as the HA-2 determ i n a n t ,
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ABSTRACT
Analysis of the cytotoxic effector mechanisms by which T-cell subsets mediate graft-versus-leukemia (GVL) activity
is complicated by systems that use unfractionated T cells and leukemias that express alloantigens in addition to
t u m o r- s p e c i fic antigens. In this study, we used MMB1.10, a myeloid leukemia of C57Bl/6 (B6) origin, to e x a m i n e
the cytolytic pathways employed by syngeneic GVL-mediating, and there f o re tumor antigen–specific, T-cell sub-
sets. Wright-Giemsa staining and flow cytometric analysis indicated that MMB1.10 cells exhibited the morphology
and markers most consistent with a monocytic–myeloid origin. Although reverse transcription–polymerase chain
reaction analysis revealed that MMB1.10 cells expressed tumor necrosis factor (TNF) receptor types I and II, in
v i t ro assays suggested that these cells were resistant to TNF-α–mediated cytotoxicity. For study of in vivo GVL
responses, mice were challenged with MMB1.10 cells, lethally irradiated, and administered anti-Thy-1–tre a t e d
( T-cell–depleted) bone marrow (ATBM) either alone or in combination with T-cell subsets from MMB1.10-pre s e n-
sitized mice. In re g a rd to CD4+ donor T cells, 4 × 1 06 M M B 1 . 1 0 - p resensitized wild-type (w t) cells exhibited
i n c reased GVL responses and survival values relative to tumor-challenged recipients of ATBM only. CD4+ T cells
f rom either perf o r i n - d e ficient (p f po) or Fas ligand (FasL)-deficient (g l d) mice exhibited a lower level of GVL activity
but did not produce any long-term survivors. Recipients of 5 × 1 06 w t B6 CD8+ T cells had significantly improved
survival relative to tumor-challenged mice that received ATBM only. The same dose of gld CD8+ T cells exhibited
a reduced but significant level of GVL activity, whereas cells from mice that were perf o r i n - d e ficient or cytotoxicity
doubly deficient (c d d) (ie, lacking perforin and FasL) exhibited no discernable GVL activity. Doubling the g l d C D 8+
T-cell dose to 107 cells resulted in further improved survival of recipients. We conclude that GVL effects mediated
by CD4+ T cells can depend on either perforin- or FasL-mediated mechanisms, whereas the CD8+ T-cell subset is
heavily dependent on perforin-mediated cytotoxicity.
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have expression limited to hematopoietic cells and can thus
potentially serve as tumor cell targets for donor T cells,
with minimal risk of GVHD development [14]. It is also
likely that tumor- s p e c i fic antigens may exist, as autologous
and syngeneic HSC grafts can be manipulated to mediate
GVL effects with or without a concomitant, autoimmune-
like GVHD [15-18]. 
T cells can induce GVL responses through multiple
pathways, depending on their subset functional capabilities,
and involve either cytokine-mediated activation of other
e ffector cells (eg, through infla m m a t o ry molecules such as
i n t e rf e ron [IFN]-γ) or direct cytolytic activity. As for the lat-
t e r, both CD4+ and CD8+ cytotoxic T lymphocytes (CTLs)
can induce tumor target cell apoptosis through several
means, including (1) exocytosis of cytotoxic granules con-
taining perforin and granzymes, (2) the ligation of Fas ligand
(FasL) to target cell Fas, and (3) the binding of tumor necro-
sis factor (TNF)-α to tumor cell receptors. CD4+ T cells
possessing cytolytic activity have classically been considere d
to mediate killing via FasL [19]. Perforin-using CD4+ T- c e l l
clones have been described in vitro, but few in vivo systems
have clearly identified a role for this exotic subset [20].
Although in vitro work has delineated the cytolytic functions
of antileukemic T-cell clones [21], the cytotoxic mechanisms
involved in GVL responses remain poorly characterized,
especially in the context of myeloid leukemias.
We have previously described a mouse model of syn-
geneic GVL activity that features CD4+ and CD8+ T- c e l l
responses against a c-m y c–induced myeloid leukemia of
C57Bl/6 (B6) origin [22]. In the present study, we demon-
strate that CD4+ and CD8+ T-cell–mediated GVL activ-
ity against MMB1.10, another B6 c-m y c–induced m y e l o i d
leukemia, is not mediated by TNF-α. Instead, CD4+ T- c e l l
GVL responses can be mediated by either FasL or per-
forin mechanisms alone. In contrast, CD8+ T-cell GVL
responses are heavily reliant on perforin, and only second-
arily on FasL. 
MATERIALS AND METHODS
M i c e
Wild-type (w t) C57Bl/6 (B6),  perf o r i n - d e f i c i e n t
C 5 7 B l / 6 - P f pt m 1 S d z (p f po), and FasL-deficient B6Smn.C3H-
F a s lg l d (g l d) mice (both deficient strains are on a B6 [H2b]
i n b red background), were purchased directly or derived
f rom breeding stock from the Jackson Laboratory (Bar
H a r b o r, ME). 
Cytotoxicity doubly deficient (cdd) mice (ie, lacking both
p e rforin and FasL genes) were produced by interbre e d i n g
(pfpo × gld) F1 mice. cdd mice were screened by allele-specific
polymerase chain reaction (PCR) primers for detection of
the wild-type perforin allele (sequences: 5′-gct cca cag agc
atg ctt acc aca ggc tca-3′ and 5 ′-tgg gca gca gtc ctg gtt ggt
gac ctt-3′). In addition, previously described primers were
used to detect mutant perforin (neomycin cassette-specific),
and wild-type and mutant FasL [23,24]. PCR reactions were
p e rf o rmed using Ready-To-Go PCR Beads (Amersham
P h a rmacia Biotech, Arlington Heights, IL) and a Perkin-
Elmer Applied Biosystems GeneAmp PCR System 9700
(Perkin-Elmer, Foster City, CA). A Touchdown PCR proto-
col was used to detect FasL alleles: 3 minutes at 94°C;
1 2 cycles of 20 seconds at 94°C, 30 seconds at 56°C (with a
decrement of 0.5°C for each cycle), and 50 seconds at 72°C;
25 cycles of 20 seconds at 94°C, 30 seconds at 50°C, and
5 0 seconds at 72°C; and final extension for 2 minutes at
72°C. To detect perforin alleles, the Touchdown PCR pro-
tocol included 3 minutes at 94°C; 12 cycles of 20 seconds at
94°C, 30 seconds at 64°C (with a decrement of 0.5°C for
each cycle), and 35 seconds at 72°C; 25 cycles of 20 seconds
at 94°C, 30 seconds at 58°C, and 35 seconds at 72°C; and
final extension for 2 minutes at 72°C. Product size was
determined by electrophoresing the samples on an agarose
gel and staining with ethidium bromide.
Male w t and p f po m i c e used as donors were between the
ages of 7 and 12 weeks, whereas male cdd and gld mice used
as donors were between the ages of 5 and 6 weeks. Male wt
mice between the ages of 9 and 16 weeks were used as recip-
ients. Mice were kept in a sterile environment in microisola-
tors at all times and were provided with acidified water and
autoclaved food ad libitum.
Cell Lines 
WEHI164, a methylcholanthrene-induced fibro s a r-
coma, was obtained from the American Type Culture Col-
lection (Manassas, VA). MMB1.10, a c- m y c– t r a n s f o rm e d
myeloid leukemia line, was cloned from the ascites of a B6
mouse that had been injected with a c-m y c– e n c o d i n g
Moloney murine leukemia virus (MMLV) construct, as pre-
viously described [25]. 
M e d i a
P h o s p h a t e - b u ff e red saline (PBS) supplemented with
0.1% bovine serum albumin (BSA) (Sigma, St Louis, MO)
was used for all in vitro manipulations of donor bone mar-
row and lymphocytes. Immediately before injection, cells
w e re washed and resuspended in PBS alone. Culturing of
cell lines and in vitro assays were perf o rmed in RPMI-
1640 supplemented with 10% fetal bovine serum (Gibco,
Grand Island, NY), 5.5 × 1 0– 5 mol/L 2-merc a p t o e t h a n o l ,
2 mmol/L L-glutamine, 50 IU/mL penici llin,  and
5 0 µg/mL streptomycin. 
Monoclonal Antibodies
Ascitic fluids containing monoclonal antibodies (mAbs)
specific for Thy-1.2 ( J1j), CD4 (RL172), CD8 (3.168),
NK1.1 (PK136) , and rat immunoglobulin G (IgG)
(MAR18.5; a gift from Dr. Robert Levy, University of
Miami, Miami, FL) were used for preparation of cellular
grafts. The anti-B220 14.8 hybridoma line (also a gift fro m
D r. Levy) was used to pre p a re culture supernatants. In addi-
tion, affin i t y - p u r i fied goat antimouse IgG (whole-molecule)
antibodies were purchased from Cappel (Cosa Mesa, CA).
Guinea pig serum pre p a red in our laboratory or purc h a s e d
f rom Rockland (Boyertown, PA) was used as a source of
complement for all mAb treatments. For phenotyping of
MMB1.10 cells and monitoring of cellular subset depletions
f rom transplant grafts, flu o rescein isothiocyanate– and phy-
coerythrin (PE)-conjugated versions of the following mAbs
w e re purchased from PharMingen (San Diego, CA) (clone
names given in parentheses): CD3ε (145-2C11), CD4
(RM4-5), CD8α (53-6.7), B220 (RA3-6B2), 2B4, and an iso-
type control (R35-95). Biotinylated anti-Fas mAb ( J o 2 )
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(PharMingen) and streptavidin (SA)-PE (Caltag, South San
Francisco, CA) were also used.
F l o w Cytometry
Appropriate mAbs in volumes of 25 µL were incubated
with 2 × 1 05 to 5 × 1 05 cells in the wells of a 96-well
U- b o ttom microplate for 25 minutes at 4°C, centrifuged
at 1500 rpm for 3 minutes, and washed with PBS containing
0.1% BSA and 0.01% sodium azide (wash buffer). When
applicable, SA-PE or a secondary antibody was added in a
volume of 25 µL for 25 minutes at 4°C, followed by 2 washes
with wash buff e r. Fluorescence analysis was perf o rmed on
an EPICS Profile II analyzer (Coulter, Hialeah, FL) in the
Kimmel Cancer Institute Flow Cytometry Facility.
P r eparation of Cells
Bone marrow cells were obtained from the femurs and
tibias of w t mice by flushing with PBS. To pre p a re anti-
T h y - 1 – t reated (T-cell–depleted) bone marrow (AT B M ) ,
cells were incubated with J1j mAb (at 1:100 dilution) and
complement (at 1:25 dilution) for 45 minutes at 37°C and
were washed extensively. T-cell–enriched donor cell popula-
tions were prepared by (1) treating pooled spleen and lymph
node (LN) cells with Gey balanced salt-lysing solution con-
taining 0.7% NH4Cl for removal of red blood cells and (2)
panning on a plastic petri dish precoated with a 5-µg / m L
dilution of goat antimouse IgG for 1 hour at 4°C to remove
B cells. These treatments resulted in donor populations of
90% to 95% CD3+ cells, as quantitated by fluorescent flow
cytometry. As required, the suspensions of enriched T cells
were depleted of CD4+ or CD8+ cells by treatment with the
appropriate mAb and complement for 45 minutes at 37°C.
At the same time, B220+ B and T cells were depleted by the
addition of 14.8 culture supernatant and MAR18.5 mAb
ascites to the cellular preparations. These tre a t m e n t s
reduced the targeted populations down to background levels
on flow cytometric analysis. For antileukemia pre s e n s i t i z a-
tion, mice were injected intraperitoneally with 0.5 mL PBS
containing 5 × 106 irradiated (30 Gy) MMB1.10 cells. Two
weeks later, splenocytes and LN cells were harvested for use
as donor cells in appropriate GVL assays.
S u r vival Assay for GVL Activity
One day before transplant, recipient mice were challenged
with 105 MMB1.10 cells, injected intraperitoneally in 0.5 mL
PBS. On the following day, recipient mice were lethally irr a d i-
ated with 850 cGy using a Shepherd Mark-I-68A 1 3 7Cs sourc e
(143 cGy/min), and approximately 6 hours later were injected
intravenously (IV) with either donor ATBM cells (2 × 1 06)
alone (as a negative control) or a mixture of ATBM plus
manipulated donor T-cell populations. Mice were checked
daily for morbidity and mort a l i t y, and median survival times
(MST) were determined. To determine mortality curves, sta-
tistical comparisons were perf o rmed between experimental
g roups on data pooled from 2 separate experiments or on data
f rom re p resentative experiments using the nonparametric
Tukey multiple analysis of variance. 
R everse T r a n s c r i p t i o n – Po l ymerase Chain Reaction
Total cellular RNA was pre p a red from 106 to 107
MMB1.10 cells by homogenizing in 1 mL Ultraspec
(Biotecx Laboratories, Houston, TX), separating cellular
DNA and protein by the addition of a 1:5 volume of chlo-
rof o rm, vortexing for 5 seconds, and centrifuging at
12,500 rpm for 15 minutes. The aqueous phase was trans-
ferred to a clean Eppendorf tube, and the RNA was precipi-
tated at 4°C with the addition of an equal volume of iso-
propanol and centrifugation at 12,500 rpm for 15 minutes.
The RNA pellet was washed with 75% ethanol in diethyl
p y rocarbonate (DEPC)-treated water, centrifuged again,
resuspended in 25 µl DEPC-treated water, heated to 55°C
to 65°C for 10 minutes, and stored at –20°C. Recovery of
RNA was determined by spectrophotometry. For each sam-
ple, the reverse transcription (RT) and PCR reactions were
performed in a 1-tube format using Ready-To-Go RT-PCR
Beads (Amersham). Sense and antisense primers (1 µmol/L),
1.5 µg oligo d(T), and 2 to 4 µg total RNA were added to
each reaction. TNF receptor (TNF-R) and glyceraldehyde
phosphate dehydrogenase (GADPH) primer sequences have
been previously described [26] and were provided by Dr
Keith Kelley (University of Illinois, Urbana, IL): 55-kd
TNF-R (expected product length, 368 base pair [bp]): 5′-cag
ttg caa gac atg tcg ga-3′; 3′-gac cta gca aga taa cca gg-5′;
7 5 -kd TNF-R (expected product length, 383 bp): 5′-gag tgt
gtg ctt gcg aag ct-3′ ; 3′-cga tgt aag gat gct tgg ag-5′;
GADPH (expected product length, 225 bp): 5′-gga agc ttg
tca tca atg g-3′; 3′-aga tct cgt ggt tca cac c-5′. Reactions
w e re perf o rmed using a Perkin-Elmer Applied Biosys-
tems GeneAmp PCR System 9700. Cycling conditions were
30 minutes at 42°C; 2 minutes at 94°C; 30 cycles of 30 sec-
onds at 94°C, 45 seconds at 55°C, and 45 seconds at 72°C;
and final extension for 7 minutes at 72°C. Product size was
determined by electrophoresing the samples on an agarose
gel and staining with ethidium bromide.
TNF Sensitivity Assa y s
Assay conditions to determine the sensitivity of MMB1.10
to exogenous TNF-mediated cytotoxicity were based on
p revious studies [26]. MMB1.10 and WEHI164 cells were
c u l t u red overnight at 2 × 1 04 cells/well in a volume of 100 µL
in 96-well flat-bottom plates. Media (100 µL) containing
either actinomycin D alone (0.5 µg/mL final) or actino-
mycin D and titrated concentrations of recombinant m u r i n e
T N F -α ( P e p rotech, Rocky Hill, NJ) were added to appro-
priate quadruplicate wells. After 22 hours, 70 µL was aspi-
rated from each well before the addition of 50 µL 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro m i d e
(MTT) (final concentration, 1 mg/mL). After a 4-hour
incubation at 37°C, 50 µL medium was aspirated, and
150 µL acidified isopropanol (0.04N HCl) was added to
each well. The medium in each well was then extensively
pipetted to dissolve crystals before measurement of each
well’s absorbance at 540 nm.
RESULTS
MMB1.10 Cell Phenotype 
The lineage of the c-m y c–induced MMB1.10 leukemia
cells was investigated by flow cytometric phenotype analysis,
and the cells were found to express high levels (>75% posi-
tively staining cells) of surface H2Kb, H2Db, H2I-Ab, B7-1,
B7-2, LFA-1, Mac-1, CD11c, the macrophage scavenger
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re c e p t o r, and Fas. The cells displayed low levels (5% to 10%
positive cells) of B220, CD13, and FasL and did not expre s s
Ly6G or the ery t h roid marker TER-119 (Table 1). This phe-
notype is consistent with a monocytic–myeloid lineage. In
addition, Wright-Giemsa staining of MMB1.10 cells
revealed that they are mononuclear and lack a “cart w h e e l ”
appearance, arguing against a granulocytic or plasma cell lin-
eage (Figure 1). This determination was also supported by
the positive but very sparse myeloperoxidase staining of the
cytoplasm of MMB1.10 cells (not shown), similar to that
o b s e rved with human myelomonocytic leukemias (M4 classi-
fication). The high expression of major histocompatibility
complex (MHC) class I and II proteins and costimulatory
molecules suggested that MMB1.10 cells might be capable of
antigen presentation, and the presence of surface Fas mole-
cules suggested that the cells could be susceptible to FasL-
mediated apoptosis.
MMB1.10 Cell Expression of TNF Receptors 
RT-PCR analysis was perf o rmed to ascertain whether
MMB1.10 cells expressed the TNF type I or II death-signaling
receptors, as the expression levels of these surface molecules
can be below the threshold of detection by flow cytometry
[27]. Production of messenger RNA (mRNA) for both TNF
receptors was evident (Figure 2). However, despite the pres-
ence of these receptors, MMB1.10 cells were resistant to
exogenous TNF-α–mediated cytotoxicity over a concentra-
tion range of 0.02 to 20 ng/mL, in contrast to the TNF-α–
susceptible WEHI164 cell line, which was highly sensitive
at all concentrations tested (Figure 3). These findings sug-
gest that MMB1.10 cells may be incapable of transmitting
apoptotic signals via the TNF receptor pathway. 
Role of P e r f orin or FasL in GVL Responses 
of CD4 + T Cells
To assess the importance of either perforin or FasL
mechanisms of cytotoxicity in CD4+ T-cell–mediated GVL
a c t i v i t y, B6 mice were initially injected intraperitoneally
with 1 × 1 05 MMB1.10 cells on day –1 and exposed to 8.5 Gy
irradiation on day 0. After 6 hours, the mice were adminis-
t e red 2 × 1 06 ATBM cells either alone or in combination
with 4 × 106 CD4+ T cells from MMB1.10-primed pfpo, gld,
or wt mice (all on the B6 strain background). As shown in
F i g u re 4, the majority of mice injected with ATBM cells
alone and then challenged with MMB1.10 cells died rapidly,
with an MST of 15 days and a 100% fatality rate by day 32.
MMB1.10-challenged mice that also received w t C D 4+
T cells exhibited improved survival (P ≤ .05), with an MST
of 23 days and a 20% long-term survival rate until the end
of observation at day 55. Recipients of g l d or p f po C D 4+
T cells exhibited nearly identical but weaker GVL activity,
although such cells still had significantly prolonged survival
(P ≤ .01 compared with the control ATBM + MMB1.10
group) at an MST of 20 days; there were no long-term sur-
vivors. These results suggest that CD4+ T cells mediate
GVL effects against MMB1.10 leukemia through either
perforin or FasL cytotoxic pathways.
C D 8 + T Cells Rely Hea v i l y on P e r f orin to Mediate
GVL Activity 
To ascertain the cytotoxic mechanism used by the CD8+
T-cell component of syngeneic GVL responses, B6 mice
were injected intraperitoneally with 1 × 105 MMB1.10 cells
and the next day (day 0) exposed to 8.5 Gy of ionizing radia-
tion. Six hours later, mice were administered 2 × 106 ATBM
cells alone or in combination with 5 × 1 06 C D 8+ T cells from
MMB1.10-presensitized pfpo, gld, or wt B6 mice. Again, mice
challenged with MMB1.10 and administered ATBM cells
alone died rapidly, with an MST of 18 days ( F i g u re 5). In
contrast, mice that also received w t C D 8+ T cells exhibited
Table 1. Phenotype of MMB1.10 Cells*
mAb Directed to Positive (%)
B220 5.0
Ly6G 0.2
CD13 8.9
H2K b 96.2
H2D b 77.2
H2I-Ab 89.8
B7-1 90
B7-2 100
LFA-1 92.5
Mac-1 99.1
CD11c 92.5
Scavenger receptor 99.6
Fas (CD95) 100
Fas ligand 5.6
TER-119 0.3
FITC isotype control 0.8
PE isotype control 1.0
*MMB1.10 cells were stained with fluorochrome-conjugated mAb and ana-
lyzed by flow cytometry.
Figure 1. Wright-Giemsa–stained MMB1.10 leukemia cells.
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significantly prolonged survival (P ≤ .001), with an MST of
>43 days and a 50% rate of survival for at least 55 days.
MMB1.10-challenged mice that received ATBM and g l d
CD8+ T cells also exhibited GVL effects, with an MST of
35 days (P ≤ .04), but there were no long-term surv i v o r s .
GVL activity in the absence of FasL was significantly l e s s
than that of an equal number of w t C D 8+ T cells (P ≤
.03), suggesting a potential role for FasL-mediated cytotoxi-
city in the response. However, this possibility was partly dis-
counted by the results of MMB1.10-challenged mice that
were administered ATBM and pfpo CD8+ T cells, which did
not exhibit any GVL activity (P ≤ .99); these mice had an
MST of 19 days, and there were no long-term survivors. A
similar lack of GVL activity was observed in recipients of
cdd CD8+ T cells (P > .99), with an MST of 17 days. 
To further test whether there was any potential for
FasL-mediated GVL activity, the dosage of donor CD8+
T cells was doubled (1 × 1 07 cells) for each experimental
g roup. As before, mice challenged with MMB1.10 and
administered ATBM cells alone died rapidly, with an MST
of 18 days; there were no long-term survivors (Figure 6). In
contrast, recipients of w t C D 8+ T cells exhibited a 100%
s u rvival rate (P ≤ .001). MMB1.10-challenged mice that
received ATBM and gld CD8+ T cells again exhibited inter-
mediate GVL effects, with an MST of >55 days (P ≤ .001)
and a 66% long-term survival rate. Most import a n t l y, the
GVL activity of mice receiving pfpo or cdd CD8+ T cells was
not enhanced at all over that of mice in the previous, lower
dosage experiment, with recipient mice in the 2 experiments
demonstrating similar MST values (19 and 18 days, respec-
tively). These findings suggest that CD8+ T cells relied pri-
marily, if not entirely, on perforin-mediated cytotoxicity to
mediate GVL effects against the MMB1.10 leukemia cells.
DISCUSSION
GVL activity can be induced by T cells present in allo-
geneic HSC grafts and, in some settings, in autologous or syn-
geneic grafts as well [15-18]. Of note, the myeloid leukemias
seem most susceptible to GVL effects, although very little is
known about these responses. Murine myeloid GVL models
have been hindered in the past by the limited availability of
myeloid cell lines, especially those that do not involve the
e x p ression of re t roviral antigens. Our model for GVL
responses features a myeloid leukemia that was transform e d
t h rough transduction with a c -m y c c o n s t ruct and does not
result in any detectable viru s - related protein expression [22].
F u rt h e rm o re, c-m y c is a frequently mutated gene in leukemias
and lymphomas, and hence, in contrast to other cell lines [28-
30], the leukemia-specific antigens displayed by MMB1.10
may more accurately re flect the direct and indirect effects of
oncogenesis, rather than those of re t roviral infection. 
Although a syngeneic model is appropriate for study of
leukemia antigen–restricted GVL responses, clinical GVL
activity has been observed to occur more often in recipients
of allogeneic, rather than autologous or syngeneic, HSC
grafts [12,13]. However, it remains uncertain to what degree
GVL activity reflects bona fide leukemia antigen–specific
responses versus a variant or subset of GVHD re s p o n s e s
mounted against alloantigens present on leukemic cells. Iso-
lated clinical re p o rts have described allogeneic HSC
patients who have experienced GVL effects without obvious
GVHD, and vice versa [13]. Analogous separation of
GVHD and GVL activity has been achieved in several ani-
mal models [22,31-34], and both experimental and clinical
studies have indicated that syngeneic or autologous GVL
responses can be induced [15-18,22]. Finally, several studies
have used r a s, b c r- a b l, and p ro t e i n a s e - 3 as sources of tumor
antigens to establish autologous T-cell clones [35-37]. How-
ever, despite the capacity of T cells with such tumor-related
specificities to be induced in vitro, it is still contro v e r s i a l
whether such cells can actually be effective under physio-
logic conditions in vivo.
The reliance of GVL on T cells has been inferred from
re p o rts that leukemias relapse less frequently in patients
Figure 2. mRNA expression of TNF receptors by MMB1.10. mRNA was
isolated from MMB1.10 (lanes 5-7) and WEHI164 (lanes 2-4) and reverse
transcribed to produce complementary DNA (cDNA). Primers for NADPH
(lanes 2 and 5) and TNF receptors type I (lanes 3 and 6) and II (lanes 4 and
7) were used for PCR, and the products were resolved on an agarose gel.
F i g u r e 3. MMB1.10 resistance to TNF-mediated cytotoxicity. Either
MMB1.10 or WEHI164 was cultured in the presence of actinomycin D alone
or actinomycin D along with titrated amounts of recombinant TNF-α.
1
2
3
4
5
6
7
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receiving T-cell–replete HSC grafts than in patients receiv-
ing transplants that have been depleted of T cells [12,13]. In
addition, delayed infusions of T cells into HSC re c i p i e n t s
have the capacity to counteract leukemic relapses, and in
this case T cells may be the only effective means to eradicate
the tumor burden [8,38-40]. 
Although T cells probably dominate GVL re s p o n s e s ,
studies have also identified NK cells as being involved in
antitumor activity [41,42]. It has been hypothesized that
CD4+ T cells induce GVL responses indirectly via release of
cytokines that support the functions of tumoricidal NK
cells [41]. In a similar syngeneic GVL model using another
c -m y c–induced myeloid leukemia (the MMB3.19 tumor),
CD4+ T-cell–mediated GVL activity was not dependent on
NK cells, as weekly injections of anti-NK1.1 mAb did not
a b rogate protection against MMB3.19 challenge (R.
Townsend, R.K., unpublished data). Within the CD8+ T-cell
subset, noncytolytic mechanisms also do not seem to con-
tribute significantly to GVL effects; in the current study,
t u m o r-challenged mice receiving c d d C D 8+ T cells did not
exhibit any detectable GVL activity (Figures 5 and 6). In
addition, MMB1.10 cytolysis by CD4+ and CD8+ CTLs is
not likely to be mediated through TNF-α–TNF-R interac-
tions, as MMB1.10 cells were resistant to high concentra-
tions of exogenous TNF-α (Figure 3). 
The observations described here support the notion that
GVL-mediating CD4+ T cells can mediate direct cytotoxic-
ity in vivo (Figure 4). Specifically, we found that this subset
of CD4+ T cells can rely on either FasL or, surprisingly, per-
forin pathways alone to mediate GVL effects. The perforin-
using CD4+ T cells in our model are particularly interesting,
as such cells have been characterized only rarely in vivo [43],
despite several observations in vitro [20,44,45]. Furt h e r-
m o re, a prominent role for perforin-dependent CD4+
T cells has been implicated in antitumor responses only out-
side the setting of HSC transplantation [46]. In contrast to
C D 4+ e ffects, the CD8+ CTLs involved in the MMB1.10
GVL responses depend almost entirely on the perf o r i n
pathway (Figures 5 and 6). 
Other studies of allogeneic GVL models have found
evidence of heavy reliance of CD8+ T-cell activity on per-
forin utilization. Pan et al. [47] demonstrated that T cells
present in granulocyte colony-stimulating factor (G-C S F ) –
mobilized peripheral blood stem cell transplant grafts
induced perforin-dependent GVL activity against P815
mastocytoma cells, which express only MHC class I mole-
cules. In another investigation of GVL activity against
either P815 or the MHC class I+ L1210 T-cell leukemia,
Tsukada et al. [48] concluded that CD8+ GVL activity could
be maintained while ameliorating GVH through the use of
gld donors, but not through the use of pfpo donors. Because
L1210 is resistant to TNF- and Fas-mediated apoptosis in
vitro, it is not surprising that perforin, the only other major
cytotoxic molecule available for antitumor effects, expressed
by gld donors, is sufficient to mediate GVL activity. It is
m o re interesting that gld cells can mediate GVL against
P815 cells, because this tumor is susceptible to apoptosis
induced by FasL-transfected effector cells but is resistant to
TNF-mediated cell death [48]. Analogous to GVL activity
against L1210 and to MMB1.10 in our study, this re s u l t
implies that the perforin expressed by gld C D 8+ T cells is
adequate to eliminate P815 cells.
Cytolytic functions have been better characterized in
p u re GVHD systems. Perf o r i n - d e ficient, unfractionated T cells
f rom fully allogeneic or MHC-matched mice, differing at
minor histocompatibility loci, mediated acute GVHD but
with slower kinetics [43,49,50]. However, FasL-deficient,
unfractionated T cells mediated cachexia without skin or
liver pathologic abnormalities [50]. Anti-FasL antibodies
given in vivo have confirmed that FasL expressed on unfrac-
tionated T cells seems to induce skin and liver GVHD [51].
Through the use of FasL-deficient donors, GVHD-associ-
Figure 4. Role of perforin and FasL in CD4+ T-cell–mediated GVL. B6 mice were injected with either MMB1.10 or no tumor (placebo), and in both cases were
then lethally irradiated. These mice received ATBM alone or in combination with 4 × 106 MMB1.10-primed CD4+ T cells from wt, pfpo, or gld donor B6 mice.
Results are pooled from 2 experiments (n = 9 to 10 mice per group). 
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ated lymphoid hypoplasia and dysfunction have also been
attributed to FasL, and not to perforin expression [49,50].
For other fully allogeneic models, both CD4+ and CD8+
T cells rely on perforin for induction of optimal GVHD
[43]. In contrast, other studies have re p o rted that CD4+
T-cell– mediated GVHD is heavily reliant on FasL, whereas
C D 8+ T-cell–induced disease is more dependent on per-
forin-mediated pathways [52]. Granzyme B has been found
to contribute heavily to GVHD mediated by CD8+, MHC
class I–mismatched T cells, but not to GVHD mediated by
C D 4+ T cells [53]. Through the use of neutralizing
anti–TNF-α antibodies [51,54-57], soluble TNF-α receptor
inhibitors [57], and Fas ligand–perforin doubly deficient
donor T cells [58], several investigators have also found that
many models of GVHD are also highly reliant on TNF-α
a c t i v i t y, although it is not clear whether this cytokine is
functioning directly as a cytolytic agent or as a mediator in
the development of the inflammatory response.
Of note, an earlier study warned that g l d F a s L - d e fic i e n t
T cells may be unable to induce cytotoxicity because of a
Figure 5. Role of perforin and FasL in CD8+ T-cell–mediated GVL. B6 mice were injected with MMB1.10 or no tumor (placebo) and in both cases were then
lethally irradiated. These mice received ATBM alone or in combination with 5 × 106 MMB1.10-primed CD8+ T cells from wt, pfpo, gld, or cdd donor B6 mice
(ATBM and wt or gld, n = 4 mice per group; ATBM and pfpo, n = 3; ATBM and cdd, n = 2).
Figure 6. High doses of CD8+ T cells overcome FasL-associated defects in GVL activity. B6 mice were injected with MMB1.10 or no tumor (placebo) and in both
cases were then lethally irradiated. These mice received ATBM alone or in combination with 107 MMB1.10-primed CD8+ T cells from wt, pfpo, gld, or cdd donor
B6 mice (ATBM and wt, gld, or pfpo, n = 3 mice per group; ATBM and cdd, n = 5).
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d efect during in vivo activation, and not only because of
a lack of cytotoxic Fas–FasL interactions between T cells
and their targets [49]. To rule out this possibility, we
used gld and c d d mice at 5 to 6 weeks of age and depleted
B 2 2 0+ T cells from inocula derived from these mice [50].
Both of these approaches have been effective in exclud-
ing the anergized B220+ C D 4–C D 8– T-cell subset that
arises in older g l d and c d d mice and features aberrant f u n c-
tions. Careful studies using p f po mice have confirmed that
t h e se mice are appropriate for studying antigen-specific
responses [59].
The factors that influence why particular cytolytic
mechanisms are dominantly used by GVL-mediating T cells
in our systems remain unclear. Perhaps the cytokines associ-
ated with protective GVL responses foster the development
of certain cytotoxic effector mechanisms over others. As
re p o rted pre v i o u s l y, the balance between Th1/Tc1- and
Th2/Tc2-associated cytokines present during CTL develop-
ment may influence the armamentarium used by cytotoxic
effector cells in an HSC transplant setting [60]. Regardless
of what dictates the effector mechanisms used by GVL-
mediating T lymphocytes, the patterns of cytolytic functions
employed against leukemias may differ from those brought
to bear against host tissues in GVHD [48]. This possibility
could form the basis for future therapeutic approaches to
minimize GVHD while preserving GVL activity.
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